Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont ...